Home / Conferences


BioProduction Congress 2016

BioProduction Congress: 19‒20 October 2016
Pre-Conference Workshops and Symposiums: 18 October 2016 
Post-Conference Symposiums: 21 October 2016
Citywest Hotel 
Dublin, Ireland

GPhA 2016 Fall Technical Conference

GPhA 2016 Fall Technical Conference
24−26 October 2016
Bethesda North Marriott Hotel and Conference Center
North Bethesda, MD, USA

Equivalence of Complex Drug Products: Scientific and Regulatory Challenges

Equivalence of Complex Drug Products: Scientific and Regulatory Challenges 2016
Wednesday, 9 November 2016, from 8:30 am to 5:15 pm
The New York Academy of Sciences
New York, USA

World Biosimilar Congress Europe 2016

World Biosimilar Congress Europe
14‒15 November 2016
Congress Center Basel
Basel, Switzerland 

Biosimilars North America

Biosimilars North America
16–17 November 2016
Iselin, New Jersey, USA

World Biosimilar Congress USA 2017

World Biosimilar Congress USA
23–24 May 2017
Hilton San Diego Resort and Spa 
San Diego, CA, USA

Extrapolation key issue at European biosimilars conference

The European Generic medicines Association (EGA) held its 13th EGA-European Biosimilars Group Conference in London on 23–24 April 2015.

French generics association promotes biosimilars

French generics association GEMME held its first symposium on the challenges and opportunities associated with biosimilars in France on 3 October 2014.

Topics presented at the 16th IGPA conference on generics

Topics presented at the 16th Annual IGPA Conference, held in Brussels, Belgium, 9–11 December 2013, showed that despite differences in the pharmaceutical market in different countries most appreciate the value of generics. In most cases this is driven by cost reduction.

EGA pushes for increased focus on generics and biosimilars

EGA President Ms Gudbjorg Edda Eggertsdottir, speaking at the European Generic medicines Association’s (EGA’s) conferences in London, UK (11th EGA International Symposium on Biosimilar Medicines) and in Athens, Greece (19th EGA Annual Conference); stressed the importance of keeping generics and biosimilars manufacturers within Europe, thus ensuring that high quality manufacturing jobs and know-how remains in Europe. This would benefit society and patients and increase the competitiveness and innovative capacity of the pharmaceutical industry in Europe.

Generics News Research General


Biosimilars News Research General